Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/35960

Androstenedione: Target Organs and Levels of Evidence for TR-560

Toxicology and Carcinogenesis Studies of Androstenedione (CASRN 63-05-8) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review DateRoute/Exposure LevelsStudy Laboratory
Androstenedione
63-05-8
02/25/2009Gavage
RATS & MALE MICE: 0, 10, 20, OR 50 MG/KG FEMALE MICE: 0, 2, 10, OR 50 MG/KG; 50/SEX/SPECIES
Southern Research Institute

Levels of Evidence

Male Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
May Have Been Related
  • Lung: Alveolar/bronchiolar adenoma 0/50 0/50 5/50 2/50 alveolar/bronchiolar adenoma or carcinoma (combined) 0/50 0/50 5/50 3/50
Non-Neoplastic Lesions
  • Liver: Basophilic focus; clear cell focus; eosinophilic focus
Decreased Incidences
  • Testis: Interstitial cell adenoma
  • Mononuclear cell leukemia
Female Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
May Have Been Related
  • All Organs: Mononuclear cell leukemia 5/50 11/50 18/50 15/50 (choose all organs until programmer intervention)
Non-Neoplastic Lesions
  • Pancreatic Islets: Hyperplasia
  • Exocrine Pancreas: Atrophy
Decreased Incidences
  • Mammary Gland: Fibroadenoma
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: Hepatocellular adenoma, multiple 16/50 27/50 23/50 34/50 hepatocellular adenoma (includes multiples) 32/50 38/50 29/50 43/50 hepatocellular carcinoma multiple 7/50 12/50 10/50 17/50 hepatocellular adenoma or hepatocellular carcinoma (combined includes multiples) 41/50 47/50 42/50 48/50 hepatoblastoma 3/50 8/50 7/50 8/50 hepatocellular adenoma, carcinoma, or hepatoblastoma (combined) 41/50 47/50 43/50 48/50
  • Pancreas Islet Cell: Adenoma (includes multiples) 2/50 2/50 2/50 5/49
Non-Neoplastic Lesions
  • Liver: Eosinophilic focus
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: Adenoma 14/50 16/50 18/50 28/50 carcinoma 5/50 13/50 15/50 15/50 adenoma or carcinoma 17/50 23/50 27/50 32/50
  • Pancreas Islet Cell: Adenoma 0/49 2/50 4/49 4/48
Non-Neoplastic Lesions
  • Liver: Mixed cell focus; hepatocyte, cytoplasmic vacuolization
  • Clitoral Gland: Hyperplasia; duct dilatation
  • Kidney: Glomerulus, metaplasia
  • Submandibular salivary gland: Cytoplasmic alteration
Decreased Incidences
  • Malignant Lymphoma